市場調査レポート - 241478

急性脊髄損傷(ASCI)治療薬：パイプライン評価と市場予測（2019年まで）

Acute Spinal Cord Injury (ASCI) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
発行 GlobalData
出版日 ページ情報 英文 Pages: 65
価格
急性脊髄損傷(ASCI)治療薬：パイプライン評価と市場予測（2019年まで） Acute Spinal Cord Injury (ASCI) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
出版日: 2012年05月31日 ページ情報: 英文 Pages: 65

当レポートでは、急性脊髄損傷(ASCI)の治療法の研究・開発の最新動向調査と、関連市場の将来予測とを実施し、病気の概要と対処法、全世界および主要7カ国における市場規模計測・予測（2006〜2019年）、競争構造、臨床試験の進行状況に関するパイプライン評価、今後の市場動向および企業戦略に関する戦略的考察などの情報を盛り込んで、概略以下の構成でお届けします。

第1章　目次

第2章　急性脊髄損傷：イントロダクション

  • 疾患の概要
  • 疫学
    • 発病率
  • 社会経済的状況と生活の質
  • 病因
  • 徴候
  • 診断
  • 治療と管理プラン
  • 紹介経路
  • 当レポートの構成

第3章　市場の特徴

  • 概要
  • 市場規模実績値（全世界、2006〜2011年）
  • 市場規模予測値（全世界、2011〜2019年）
  • 市場規模実績値（米国、2006〜2011年）
  • 市場規模予測値（米国、2011〜2019年）
  • 市場規模実績値（フランス、2006〜2011年）
  • 市場規模予測値（フランス、2011〜2019年）
  • 市場規模実績値（ドイツ、2006〜2011年）
  • 市場規模予測値（ドイツ、2011〜2019年）
  • 市場規模実績値（イタリア、2006〜2011年）
  • 市場規模予測値（イタリア、2011〜2019年）
  • 市場規模実績値（スペイン、2006〜2011年）
  • 市場規模予測値（スペイン、2011〜2019年）
  • 市場規模実績値（英国、2006〜2011年）
  • 市場規模予測値（英国、2011〜2019年）
  • 市場規模実績値（日本、2006〜2011年）
  • 市場規模予測値（日本、2011〜2019年）
  • 市場促進・抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 市場機会とアンメットニーズの分析
  • 主な結論

第4章　競争評価

  • 概要
  • 戦略的な競合企業の評価
  • 主な市販製品のプロファイル
    • コハク酸メチルプレドニゾロンナトリウム
  • 主な結論

第5章　パイプライン評価

  • 概要
  • 戦略的パイプライン評価
  • 開発段階別パイプライン
    • フェーズIIパイプライン
    • フェーズIパイプライン
    • 前臨床パイプライン
    • 創薬パイプライン
  • 技術傾向の分析枠組み
  • 機能メカニズム別パイプライン
  • 主な結論

第6章　治験マッピング

  • 地域別・国別の治験数（米国・EU5カ国・日本）
  • フェーズ別の治験数
  • 検証段階別の治験数
  • 有望なスポンサー
  • 急性脊髄損傷の治験に参加している上位企業10社

第7章　戦略的評価

  • 今後の市場に影響する主な事項
  • 将来の市場競争への影響

第8章　将来の市場参入企業

  • イントロダクション
  • 企業プロファイル
    • Asubio Pharmaceuticals, Inc.
    • Acorda Therapeutics, Inc.

第9章　付録

図表一覧

※ このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

Abstract

Acute Spinal Cord Injury (ASCI) Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Summary

GlobalData, the industry analysis specialist, has released its new report, "Acute Spinal Cord Injury (ASCI) Therapeutics - Pipeline Assessment and Market Forecasts to 2019". The report is an essential source of information and analysis on the global Acute Spinal Cord Injury Therapeutics market. The report identifies the key trends shaping and driving the global Acute Spinal Cord Injury Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Acute Spinal Cord Injury Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Acute Spinal Cord Injury (ASCI) Therapeutics market. Its scope includes -

  • Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Acute Spinal Cord Injury Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
  • Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
  • Analysis of the current and future competition in the seven key countries Acute Spinal Cord Injury Therapeutics market.
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Acute Spinal Cord Injury Therapeutics market.
  • Analysis of key recent licensing and partnership agreements in Acute Spinal Cord Injury Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global Acute Spinal Cord Injury Therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Acute Spinal Cord Injury Therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
  • What's the next big thing in the global Acute Spinal Cord Injury Therapeutics market landscape? - Identify, understand and capitalize.

TOC

1 Table of Contents

1 Table of Contents 3

  • 1.1 List of Tables 5
  • 1.2 List of Figures 6

2 Acute Spinal Cord Injury Therapeutics - Introduction 7

  • 2.1 Disease Overview 7
  • 2.2 Epidemiology 10
    • 2.2.1 Incidence 10
  • 2.3 Socioeconomic Status and Quality of Life 11
  • 2.4 Etiology and Pathogenesis 11
  • 2.5 Signs and Symptoms 13
  • 2.6 Diagnosis 16
  • 2.7 Treatment and Management Pattern 17
  • 2.8 Referral Pathway 19
  • 2.9 GlobalData Pipeline Report Guidance 20

3 Acute Spinal Cord Injury Therapeutics - Market Characterization 21

  • 3.1 Overview 21
  • 3.2 Acute Spinal Cord Injury Therapeutics Market Size (2006-2011) - Global 21
  • 3.3 Acute Spinal Cord Injury Therapeutics Market Forecast (2011-2019) - Global 22
  • 3.4 Acute Spinal Cord Injury Therapeutics Market Size (2006-2011) - The US 23
  • 3.5 Acute Spinal Cord Injury Therapeutics Market Forecast (2011-2019) - The US 24
  • 3.6 Acute Spinal Cord Injury Therapeutics Market Size (2006-2011) - France 25
  • 3.7 Acute Spinal Cord Injury Therapeutics Market Forecast (2011-2019) - France 26
  • 3.8 Acute Spinal Cord Injury Therapeutics Market Size (2006-2011) - Germany 27
  • 3.9 Acute Spinal Cord Injury Therapeutics Market Forecast (2011-2019) - Germany 28
  • 3.10 Acute Spinal Cord Injury Therapeutics Market Size (2006-2011) - Italy 29
  • 3.11 Acute Spinal Cord Injury Therapeutics Market Forecast (2011-2019) - Italy 30
  • 3.12 Acute Spinal Cord Injury Therapeutics Market Size (2006-2011) - Spain 31
  • 3.13 Acute Spinal Cord Injury Therapeutics Market Forecast (2011-2019) - Spain 32
  • 3.14 Acute Spinal Cord Injury Therapeutics Market Size (2006-2011) - The UK 33
  • 3.15 Acute Spinal Cord Injury Therapeutics Market Forecast (2011-2019) - The UK 34
  • 3.16 Acute Spinal Cord Injury Therapeutics Market Size (2006-2011) - Japan 35
  • 3.17 Acute Spinal Cord Injury Therapeutics Market Forecast (2011-2019) - Japan 36
  • 3.18 Drivers and Barriers for the Acute Spinal Cord Injury Therapeutics Market 37
    • 3.18.1 Drivers for the Acute Spinal Cord Injury Therapeutics Market 37
    • 3.18.2 Barriers for the Acute Spinal Cord Injury Therapeutics Market 37
  • 3.19 Opportunity and Unmet Need Analysis 37
  • 3.20 Key Takeaway 38

4 Acute Spinal Cord Injury Therapeutics - Competitive Assessment 39

  • 4.1 Overview 39
  • 4.2 Strategic Competitor Assessment 39
  • 4.3 Product Profile for the Major Marketed Products in the Acute Spinal Cord Injury Therapeutics 40
    • 4.3.1 Methylprednisolone Sodium Succinate 40
  • 4.4 Key Takeaway 41

5 Acute Spinal Cord Injury Therapeutics - Pipeline Assessment 42

  • 5.1 Overview 42
  • 5.2 Strategic Pipeline Assessment 42
  • 5.3 Acute Spinal Cord Injury Therapeutics Pipeline - Pipeline by Phase of Development 43
    • 5.3.1 Acute Spinal Cord Injury Therapeutics - Phase II Pipeline 43
    • 5.3.2 Acute Spinal Cord Injury Therapeutics - Phase I Pipeline 43
    • 5.3.3 Acute Spinal Cord Injury Therapeutics - Preclinical Phase 44
    • 5.3.4 Acute Spinal Cord Injury Therapeutics - Discovery Pipeline 44
  • 5.4 Technology Trends Analytic Framework 45
  • 5.5 Acute Spinal Cord Injury Therapeutics Market - Pipeline by Mechanism of Action 47
  • 5.6 Key Takeaway 47

6 Acute Spinal Cord Injury Therapeutics - Clinical Trials Mapping 48

  • 6.1 Clinical Trials by Region/Country (The US, EU5 and Japan) 48
  • 6.2 Clinical Trials by Phase 49
  • 6.3 Clinical Trials by Trial Status 50
  • 6.4 Prominent Sponsors 51
  • 6.5 Top 10 Companies Participating in Acute Spinal Cord Injury Therapeutics Clinical Trials 52

7 Acute Spinal Cord Injury Therapeutics - Strategic Assessment 53

  • 7.1 Key Events Impacting the Future Market 53
  • 7.2 Implications for Future Market Competition 54

8 Acute Spinal Cord Injury Therapeutics - Future Players 55

  • 8.1 Introduction 55
  • 8.2 Company Profiles 56
    • 8.2.1 Asubio Pharmaceuticals, Inc. 56
    • 8.2.2 Acorda Therapeutics, Inc. 56

9 Acute Spinal Cord Injury Therapeutics - Appendix 58

  • 9.1 Market Definitions 58
  • 9.2 Bibliography 58
  • 9.3 Acronyms 60
  • 9.4 Research Methodology 61
    • 9.4.1 Coverage 61
    • 9.4.2 Secondary Research 61
    • 9.4.3 Forecasting 62
    • 9.4.4 Primary Research 64
    • 9.4.5 Expert Panel Validation 65
  • 9.5 Contact Us 65
  • 9.6 Disclaimer 65

List of Tables

1.1 List of Tables

  • Table 1: KOL Insights, Duration-based Classification of Acute Spinal Cord Injury 8
  • Table 2: Incidence Pool of Acute Spinal Cord Injury in Seven Major Markets 10
  • Table 3: KOL Insights, Incidence of Acute Spinal Cord Injury in the US and the UK 10
  • Table 4: American Spinal Injury Association Impairment Scale 16
  • Table 5: KOL Insights, Diagnosis of Acute Spinal Cord Injury in the US and the UK 16
  • Table 6: KOL Insights, Guidelines for acute SCI in the US and the UK 17
  • Table 7: KOL Insights, Pharmacological Treatment for Acute Spinal Cord Injury in the US and the UK 17
  • Table 8: KOL Insights, Referral Pathway for Acute Spinal Cord Injury in the US and the UK 19
  • Table 9: Acute Spinal Cord Injury Therapeutics Market, Global, Revenue, ($'000), 2006-2011 22
  • Table 10: Acute Spinal Cord Injury Therapeutics Market, Global, Forecast ($'000), 2011-2019 22
  • Table 11: Acute Spinal Cord Injury Therapeutics Market, The US, Revenue ($'000), 2006-2011 23
  • Table 12: Acute Spinal Cord Injury Therapeutics Market, The US, Forecast ($'000), 2011-2019 24
  • Table 13: Acute Spinal Cord Injury Therapeutics Market, France, Revenue ($'000), 2006-2011 25
  • Table 14: Acute Spinal Cord Injury Therapeutics Market, France, Forecasts ($'000), 2011-2019 26
  • Table 15: Acute Spinal Cord Injury Therapeutics Market, Germany, Revenue ($'000), 2006-2011 27
  • Table 16: Acute Spinal Cord Injury Therapeutics Market, Germany, Forecast ($'000), 2011-2019 28
  • Table 17: Acute Spinal Cord Injury Therapeutics Market, Italy, Revenue ($'000), 2006-2011 29
  • Table 18: Acute Spinal Cord Injury Therapeutics Market, Italy, Forecast ($'000), 2011-2019 30
  • Table 19: Acute Spinal Cord Injury Therapeutics Market, Spain, Revenue ($'000), 2006-2011 31
  • Table 20: Acute Spinal Cord Injury Therapeutics Market, Spain, Forecast ($'000), 2011-2019 32
  • Table 21: Acute Spinal Cord Injury Therapeutics Market, The UK, Revenue ($'000), 2006-2011 33
  • Table 22: Acute Spinal Cord Injury Therapeutics Market, The UK, Forecast ($'000), 2011-2019 34
  • Table 23: Acute Spinal Cord Injury Therapeutics Market, Japan, Revenue ($'000), 2006-2011 35
  • Table 24: Acute Spinal Cord Injury Therapeutics Market, Japan, Forecast ($'000), 2011-2019 36
  • Table 25: KOL Insights, Current Unmet Need for Acute Spinal Cord Injury in the US, Germany and Japan 37
  • Table 26: KOL Insights, Limitations of Currently Available Treatment Options for Acute Spinal Cord Injury in the US and the UK 39
  • Table 27: KOL Insights, Research for Future Treatment Options for Acute Spinal Cord Injury in the US and the UK 42
  • Table 28: Acute Spinal Cord Injury Therapeutics - Phase II Clinical Pipeline, 2012 43
  • Table 29: Acute Spinal Cord Injury Therapeutics - Phase I Clinical Pipeline, 2012 43
  • Table 30: Acute Spinal Cord Injury Therapeutics - Preclinical Pipeline, 2012 44
  • Table 31: Acute Spinal Cord Injury Therapeutics - Discovery Pipeline, 2012 44
  • Table 32: Acute Spinal Cord Injury Therapeutics, Clinical Trials by Country, 2012 48
  • Table 33: Acute Spinal Cord Injury Therapeutics Market, Clinical Trials by Phase, 2012 49
  • Table 34: Acute Spinal Cord Injury Therapeutics, Clinical Trials by Trial Status, 2012 50
  • Table 35: Acute Spinal Cord Injury Therapeutics, Prominent Sponsors, 2012 52
  • Table 36: Acute Spinal Cord Injury Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2012 52
  • Table 37: Asubio Pharmaceuticals, Pipeline for Acute Spinal Cord Injury, 2012 56
  • Table 38: Acorda Therapeutics - Central Nervous System, Pipeline Products, 2012 57

List of Figures

1.2 List of Figures

  • Figure 1: Map of Spinal Column 8
  • Figure 2: Spinal Cord after Injury 9
  • Figure 3: Acute Spinal Cord Injury Therapeutics Market - Spinal Cord Injury Causes 11
  • Figure 4: Formation of Secondary Injury in the Spinal Cord Injury 12
  • Figure 5: Effects of Complete Spinal Cord Injury 13
  • Figure 6: Quadriplegia and Paraplegia in Acute Spinal Cord Injury 14
  • Figure 7: Effects of Spinal Cord Injury 15
  • Figure 8: Treatment Options for Acute Spinal Cord Injury 18
  • Figure 9: Referral Pathway for Acute Spinal Cord Injury 19
  • Figure 10: Acute Spinal Cord Injury Therapeutics Market, Global, Revenue ($'000), 2006-2011 21
  • Figure 11: Acute Spinal Cord Injury Therapeutics Market, Global, Forecast ($'000), 2011-2019 22
  • Figure 12: Acute Spinal Cord Injury Therapeutics Market, The US, Revenue ($'000), 2006-2011 23
  • Figure 13: Acute Spinal Cord Injury Therapeutics Market, The US, Forecast ($'000), 2011-2019 24
  • Figure 14: Acute Spinal Cord Injury Therapeutics Market, France, Revenue ($'000), 2006-2011 25
  • Figure 15: Acute Spinal Cord Injury Therapeutics Market, France, Forecast ($'000), 2011-2019 26
  • Figure 16: Acute Spinal Cord Injury Therapeutics Market, Germany, Revenue ($'000), 2006-2011 27
  • Figure 17: Acute Spinal Cord Injury Therapeutics Market, Germany, Forecast ($'000), 2011-2019 28
  • Figure 18: Acute Spinal Cord Injury Therapeutics Market, Italy, Revenue ($'000), 2006-2011 29
  • Figure 19: Acute Spinal Cord Injury Therapeutics Market, Italy, Forecast ($'000), 2011-2019 30
  • Figure 20: Acute Spinal Cord Injury Therapeutics Market, Spain, Revenue ($'000), 2006-2011 31
  • Figure 21: Acute Spinal Cord Injury Therapeutics Market, Spain, Forecast ($'000), 2011-2019 32
  • Figure 22: Acute Spinal Cord Injury Therapeutics Market, The UK, Revenue ($'000), 2006-2011 33
  • Figure 23: Acute Spinal Cord Injury Therapeutics Market, The UK, Forecast ($'000), 2011-2019 34
  • Figure 24: Acute Spinal Cord Injury Therapeutics Market, Japan, Revenue ($'000), 2006-2011 35
  • Figure 25: Acute Spinal Cord Injury Therapeutics Market, Japan, Forecast ($'000), 2011-2019 36
  • Figure 26: Strategic Competitor Assessment of the Marketed Products in Acute Spinal Cord Injury, 2011 40
  • Figure 27: Acute Spinal Cord Injury Therapeutics Pipeline by Phase of Development, 2012 43
  • Figure 28: Technology Trends Analytic Framework of the Acute Spinal Cord Injury Therapeutics Pipeline, 2012 45
  • Figure 29: Technology Trends Analytic Framework of the Acute Spinal Cord Injury Therapeutics Pipeline - Description, 2012 46
  • Figure 30: Acute Spinal Cord Injury Therapeutics, Pipeline by Mechanism of Action, 2012 47
  • Figure 31: Acute Spinal Cord Injury Therapeutics, Clinical Trials by Country, 2012 48
  • Figure 32: Acute Spinal Cord Injury Therapeutics, Clinical Trials by Phase (%), 2012 49
  • Figure 33: Acute Spinal Cord Injury Therapeutics Market - Clinical Trials by Trial Status, 2012 50
  • Figure 34: Acute Spinal Cord Injury Therapeutics, Overall Sponsors (%), 2012 51
  • Figure 35: Acute Spinal Cord Injury Therapeutics, Prominent Sponsors (%), 2012 51
  • Figure 36: Acute Spinal Cord Injury Therapeutics Market, Drivers and Barriers, 2011 53
  • Figure 37: Implications for Future Market Competition in the Acute Spinal Cord Injury Therapeutics Market, 2011 54
  • Figure 38: Acute Spinal Cord Injury Therapeutics Market - Future Players, 2012 55
  • Figure 39: GlobalData Market Size Estimation 62
  • Figure 40: GlobalData Market Forecasting Model 64

「急性脊髄損傷(ASCI)治療薬：パイプライン評価と市場予測（2019年まで）」は2012年05月31日にグローバルデータより発行されました。 当レポートはPages: 65で構成され、税抜￥417,517より販売しています。
Back to Top